{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:42:53Z","timestamp":1790030573581,"version":"4.0.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,6]],"date-time":"2014-11-06T00:00:00Z","timestamp":1415232000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s13318-014-0235-4","type":"journal-article","created":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T15:33:34Z","timestamp":1415979214000},"page":"45-54","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["CYP3A4-based drug\u2013drug interaction: CYP3A4 substrates\u2019 pharmacokinetic properties and ketoconazole dose regimen effect"],"prefix":"10.1007","volume":"41","author":[{"given":"Xavier","family":"Boulenc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Hermabessi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Zobouyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Donazzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Ollier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,6]]},"reference":[{"issue":"7","key":"235_CR1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","volume":"31","author":"TD Bjornsson","year":"2003","unstructured":"Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S et al (2003) The conduct of in vitro and in vivo drug\u2013drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31(7):815\u2013832","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"235_CR2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1515\/DMDI.2011.031","volume":"26","author":"X Boulenc","year":"2011","unstructured":"Boulenc X, Barberan O (2011) Metabolic-based drug\u2013drug interactions prediction, recent approaches for risk assessment along drug development. Drug Metabol Drug Interact 26(4):147\u2013168","journal-title":"Drug Metabol Drug Interact"},{"issue":"5","key":"235_CR3","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1365-2125.2005.02483.x","volume":"60","author":"HS Brown","year":"2005","unstructured":"Brown HS, Ito K, Galetin A, Houston JB (2005) Prediction of in vivo drug\u2013drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Pharmacol 60(5):508\u2013518","journal-title":"Br J Pharmacol"},{"key":"235_CR4","unstructured":"Djebli N, Rauch C, Fabre D, Boulenc X (2009) Quantification of the pharmacokinetic inhibition of a CYP3A4\/CYP2D6 substrate with low hepatic first pass effect and long terminal half-life; importance of study design and inhibition mechanism: a simulation study. Global Metabolism and Pharmacokinetics, Poster at ISSX meeting, Baltimore, USA"},{"key":"235_CR8","unstructured":"European Medicines Agency Guideline on the Investigation of Drug Interactions (2012) Committee for human medicinal products (CHMP). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/07\/WC500129606.pdf . Accessed 4 July 2013"},{"issue":"3","key":"235_CR6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0009-9236(98)90172-2","volume":"64","author":"DJ Grenblatt","year":"1998","unstructured":"Grenblatt DJ, Wright CE, von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM et al (1998) Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther 64(3):237\u2013247","journal-title":"Clin Pharmacol Ther"},{"key":"235_CR7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2125.2010.03799.x","volume":"71","author":"EJ Guest","year":"2011","unstructured":"Guest EJ, Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT, Houston JB, Galetin A (2011) Assessment of algorithms for predicting drug\u2013drug interaction via inhibition mechanisms: comparison of dynamic and static models. Br J Clin Pharmacol 71:72\u201387","journal-title":"Br J Clin Pharmacol"},{"key":"235_CR5","unstructured":"Guidance for Industry (2012) Drug Interaction Studies\u2014Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm"},{"key":"235_CR9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/17425250802691074","volume":"5","author":"M Jamei","year":"2009","unstructured":"Jamei M, Marciniack S, Feng K, Barnett A, Tucker G, Rostani-Hodjegan A (2009) The Simcyp population\u2014based ADME simulator. Expert Opin Metab Drug Toxicol. 5:211\u2013223","journal-title":"Expert Opin Metab Drug Toxicol."},{"issue":"4","key":"235_CR10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.clpt.2004.07.003","volume":"76","author":"AL Masica","year":"2004","unstructured":"Masica AL, Mayo G, Wilkinson GR (2004) In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin Pharmacol Ther 76(4):341\u2013349","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"235_CR11","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.105.093229","volume":"316","author":"RS Obach","year":"2006","unstructured":"Obach RS, Walsky RL, Venkatakrishnan K, Garman EA, Houston JB, Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug\u2013drug interactions. J Pharmacol Exp Ther 316(1):336\u2013348","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"235_CR12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/clpt.1994.60","volume":"55","author":"KT Olkkola","year":"1994","unstructured":"Olkkola KT, Backman JT, Neuvonen PJ (1994) Midazolam should be avoided in patient receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55(5):481\u2013485","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"235_CR13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejps.2011.04.008","volume":"43","author":"YK Rowland","year":"2011","unstructured":"Rowland YK, Walsky RL, Jamei M, Rostani-Hodjegan A, Tucker GT (2011) Prediction of time-dependent CYP3A4 drug\u2013drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. Eur J Pharm Sci 43(3):160\u2013173","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"235_CR14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","volume":"270","author":"T Shimada","year":"1994","unstructured":"Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270(1):414\u2013423","journal-title":"J Pharmacol Exp Ther"},{"key":"235_CR15","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0091270008331133","volume":"49","author":"SA Stoch","year":"2009","unstructured":"Stoch SA, Friedman E, Maes A, Yee K, Xu Y, Larson P et al (2009) Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm. J Clin Pharmacol 49:398\u2013406","journal-title":"J Clin Pharmacol"},{"key":"235_CR16","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/009127009903901102","volume":"39","author":"R Yuan","year":"1999","unstructured":"Yuan R, Flockhart DA, Balian JD (1999) Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J Clin Pharmacol 39:1109\u20131125","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"235_CR17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/0091270008331196","volume":"49","author":"P Zhao","year":"2009","unstructured":"Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH et al (2009) Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol 49(3):351\u2013359","journal-title":"J Clin Pharmacol"},{"key":"235_CR18","doi-asserted-by":"crossref","unstructured":"Zhou ZW, Zhou SF (2009) Expert Opin Drug Metab Toxicol 5(6):579\u2013605","DOI":"10.1517\/17425250902926099"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-014-0235-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-014-0235-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-014-0235-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T18:08:38Z","timestamp":1747159718000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-014-0235-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,6]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["235"],"URL":"https:\/\/doi.org\/10.1007\/s13318-014-0235-4","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,6]]}}}